Chun-Yu Cheng
Issues - Marzo 2022
Chun-Yu Cheng
Michela Starace, Aurora Alessandrini, Matilde Iorizzo, Ambra D’Altobrando, Tiziano Ferrari, Francesca Bruni, Bianca Maria Piraccini
A pilot study of intralesional methotrexate injections versus triamcinolone acetonide in patients affected by nail matrix psoriasis
Clin Exp Dermatol. 2022 Feb 2022 Feb 3. Online ahead of printMarieke M B Seyger, Matthias Augustin, Michael Sticherling, Teresa Bachhuber, Juanzhi Fang, James Hetherington, James Lucas, Sophie Meakin, Craig Richardson, Amy S Paller
Physician-reported clinical unmet needs, burden and treatment patterns of paediatric psoriasis patients: A US and EU real-world evidence study
Acta Derm Venereol. 2022 Feb 28;102:adv0066A Ruggiero, G Fabbrocini, E Cinelli, S S Ocampo Garza, E Camela, M Megna
Anti-interleukin-23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real-world practice
Clin Exp Dermatol. 2022 Mar;47(3):561-56K B Gordon, M Lebwohl, K A Papp, H Bachelez, J J Wu, R G Langley, A Blauvelt, B Kaplan, M Shah, Y Zhao, R Sinvhal, K Reich
Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis
Br J Dermatol. 2022 Mar;186(3):466-47Francesco Bellinato, Paolo Gisondi, Giampiero Girolomoni
Risk of lymphohematologic malignancies in patients with chronic plaque psoriasis: A systematic review with meta-analysis
J Am Acad Dermatol. 2022 Jan;86(1):86-96Nina Magnolo, Külli Kingo, Vivian Laquer, John Browning, Adam Reich, Jacek C Szepietowski, Deborah Keefe, Rafal Mazur, Prayashi Ghelani, Pascal Forrer, LindaAnn Wraith, Manmath Patekar
A phase 3 open-label, randomized multicenter study to evaluate efficacy and safety of secukinumab in pediatric patients with moderate to severe plaque psoriasis: 24-week results
J Am Acad Dermatol. 2022 Jan;86(1):122-130Stefano Piaserico, Paolo Gisondi, Simone Cazzaniga, Sara Di Leo, Luigi Naldi
Assessing the Risk and Outcome of COVID-19 in Patients with Psoriasis or Psoriatic Arthritis on Biologic Treatment: A Critical Appraisal of the Quality of the Published Evidence
J Invest Dermatol. 2022 Feb;142(2):355-363L Penso, R Dray-Spira, A Weill, M Zureik, E Sbidian
Psoriasis-related treatment exposure and hospitalization or in-hospital mortality due to COVID-19 during the first and second wave of the pandemic: cohort study of 1 326 312 patients in France
Br J Dermatol. 2022 Jan;186(1):59-68April W Armstrong, Ahmed M Soliman, Keith A Betts, Yan Wang, Yawen Gao, Vassilis Stakias, Luis Puig
Long-Term Benefit-Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-Analysis
Dermatol Ther (Heidelb). 2022 Jan;12(1):167-184Curdin Conrad, Christine-Elke Ortmann, Marc Vandemeulebroecke, Torben Kasparek, Kristian Reich
Nail Involvement as a Predictor of Differential Treatment Effects of Secukinumab Versus Ustekinumab in Patients with Moderate to Severe Psoriasis
Dermatol Ther (Heidelb). 2022 Jan;12(1):233-241Linda Stein Gold, Kim Papp, David Pariser, Lawrence Green, Neal Bhatia, Howard Sofen, Lorne Albrecht, Melinda Gooderham, Mindy Chen, Maria Paris, Yao Wang, Kristina Callis Duffin
Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: Results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trial
J Am Acad Dermatol. 2022 Jan;86(1):77-85James G Krueger, Iain B McInnes, Andrew Blauvelt